Prime Medicine, Inc. (PRME)

Market Cap	589.54M
Revenue (ttm)	5.98M
Net Income (ttm)	-197.34M
Shares Out	177.04M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,102,300
Open	3.530
Previous Close	3.550
Day's Range	3.270 - 3.560
52-Week Range	1.110 - 6.940
Beta	2.65
Analysts	Buy
Price Target	9.31 (+179.58%)
Earnings Date	Nov 7, 2025

About PRME

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 20, 2022
• Employees: 214
• Stock Exchange: NASDAQ
• Ticker Symbol: PRME
• Website: https://primemedicine.com

Analyst Summary

According to 6 analysts, the average rating for PRME stock is "Buy." The 12-month stock price target is $9.31, which is an increase of 179.58% from the latest price.

Price Target

$9.31

(179.58% upside)

Analyst Consensus: Buy